At the time of writing, Janux Therapeutics Inc [JANX] stock is trading at $25.56, up 0.39%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JANX shares have gain 3.23% over the last week, with a monthly amount glided 0.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on December 03, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $70 from $63. Previously, BTIG Research reaffirmed its Buy rating on December 03, 2024, and elevated its price target to $100. On November 22, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $79 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $69 on October 24, 2024. Stifel initiated its recommendation with a Buy and recommended $70 as its price target on September 06, 2024. Scotiabank started tracking with a Sector Perform rating for this stock on May 30, 2024, and assigned it a price target of $47. In a note dated March 21, 2024, BTIG Research initiated an Buy rating and provided a target price of $62 on this stock.
For the past year, the stock price of Janux Therapeutics Inc fluctuated between $22.48 and $71.71. Currently, Wall Street analysts expect the stock to reach $58.5 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $25.56 at the most recent close of the market. An investor can expect a potential return of 128.87% based on the average JANX price forecast.
Analyzing the JANX fundamentals
According to Janux Therapeutics Inc [NASDAQ:JANX], the company’s sales were 9.34M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -12.17%, Pretax Profit Margin comes in at -8.33%, and Net Profit Margin reading is -8.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.09 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Janux Therapeutics Inc [NASDAQ:JANX] has a current ratio of 58.47. Further, the Quick Ratio stands at 58.47, while the Cash Ratio is 4.21. Considering the valuation of this stock, the price to sales ratio is 161.94, the price to book ratio is 1.49.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on May 01 ’25 when 3333.0 shares were sold. Officer, ANDREW MEYER completed a deal on May 01 ’25 to buy 3333.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3334.0 shares on Apr 21 ’25.
